bit.bio
Synthetic biology / cell programming, Cambridge
Programs human iPSCs into cell types for drug discovery and toxicology. It raised $50m in its Series C in January 2026. It has 0 roles open, 0 of them in the UK.
Backed by M&G Investments.
On the Home Office register of licensed visa sponsors.
Open roles over time
Hiring momentum
Roles per weekNo data yet.
In the news
All 20 stories- ProductDrug Target Review, 20 days agobit.bio launches refined human astrocyte model for neurotoxicity assessment
- ExpansionPharmafile, 30 Sept 2026bit.bio expands human heart cell portfolio through myriamed partnership
- OtheropenPR.com, 23 Sept 2026myriamed Brings Human Cardiomyocytes to the Global Drug Discovery Market via bit.bio
- LeadershipScientific Computing World, 13 Aug 2026bit.bio announces CRISPR screening service and appoints Chief Technology Officer
- OtherBusiness Weekly, 12 Jul 2026Business for bit.bio CEO Dr Emma Pepperell can appear to an external observer to be as straightforward as ABC
- Otherthepharmaletter.com, 6 Jul 2026bit.bio cuts cost of human cell culture by 18x with new media kits